Skip to content

US · SIGA · DRUG MANUFACTURERS - SPECIALTY & GENERIC

SIGA Technologies, Inc. (SIGA) intrinsic value and stock valuation

$2.40as of 2026-11-21 · Mkt cap 218.76M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

SIGA Technologies, Inc. DCF and intrinsic value

InvestorsCraft values SIGA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SIGA’s statements →

SIGA Technologies, Inc. Graham Number

Graham Number: $4.51d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic New York City, NY 10065 siga.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$94.6M-5.4% 5y CAGRd
20112025
Net income
$23.3M-16.2% 5y CAGRd
20112025
Free cash flow
$43.1M-9.6% 5y CAGRd
20112025
Total equity
$198.8M+8.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$94.6M$138.7M$139.9M$110.8M$133.7M
Operating income$23.7M$70M$83.6M$42.7M$89.1M
Net income$23.3M$59.2M$68.1M$33.9M$69.5M
EPSd$325.4K$825K$949.6K$460.9K$909K
Operating cash flow$43.5M$48.8M$94.8M$41.6M$11.5M
Capital expenditure-$-360K-$-40K-$-20K$0.00-$-50K
Free cash flow$43.1M$48.7M$94.8M$41.6M$11.4M
Total assets$219.5M$244.3M$254.4M$195M$214.7M
Total debt$600K$550K$560K$530K$470K
Net debt-$-154.37M-$-154.85M-$-149.58M-$-98.26M-$-102.67M
Total equity$198.8M$215.8M$196.9M$170.2M$174.3M
Cash and short-term investments$155M$155.4M$150.2M$98.8M$103.1M
Income statement
20252024202320222021
Revenue$94.6M$138.7M$139.9M$110.8M$133.7M
Cost of revenue$29.7M$31.3M$17.8M$10.4M$16.6M
Gross profit$64.9M$107.4M$122.1M$100.3M$117.1M
Research and development expenses$6.53M$12.3M$16.4M$22.5M$9.94M
Selling, general and administrative expenses$3.13M$25.1M$22M$35.1M$18M
Other expenses$31.5M$0.00$0.00$0.00$0.00
Operating expenses$41.2M$37.5M$38.5M$57.6M$28M
Cost and expenses$70.9M$68.7M$56.3M$68.1M$44.6M
Interest income$6.68M$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$560K$540K$540K$520K$520K
Ebitda$31M$76.6M$88.3M$44.7M$89.8M
Operating income$23.7M$70M$83.6M$42.7M$89.1M
Total other income/expenses, net$6.7M$6.09M$4.16M$1.43M$220K
Income before tax$30.4M$76.1M$87.8M$44.1M$89.3M
Income tax expense$7.1M$16.9M$19.7M$10.2M$19.9M
Net income$23.3M$59.2M$68.1M$33.9M$69.5M
Weighted average shares outstanding$71.6M$71.3M$71.4M$72.9M$75.3M
Weighted average diluted shares outstanding$71.6M$71.8M$71.7M$73.6M$76.4M
Balance sheet
20252024202320222021
Cash and short-term investments$155M$155.4M$150.2M$98.8M$103.1M
Net receivables$3.26M$21.2M$21.1M$45.4M$83.7M
Inventory$49.1M$49.6M$64.2M$39.3M$19.5M
Total current assets$212.9M$231M$239M$185.8M$208.8M
Property, plant and equipment, net$1.09M$1.3M$1.33M$1.85M$2.37M
Goodwill and intangible assets$900K$900K$900K$900K$900K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$6.61M$13.3M$15.4M$9.25M$5.97M
Total assets$219.5M$244.3M$254.4M$195M$214.7M
Accounts payable$820K$1.34M$1.46M$3.36M$2.03M
Short-term debt$600K$550K$560K$530K$470K
Deferred revenue$10.2M$10.3M$20.8M$10.6M$3.76M
Total current liabilities$18M$25.3M$54.1M$21.5M$30.5M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.65M$3.2M$3.38M$3.36M$9.92M
Capital lease obligations$600K$550K$560K$530K$470K
Total liabilities$20.7M$28.5M$57.5M$24.9M$40.4M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-43.07M-$-22.84M-$-38.94M-$-63.8M-$-51.76M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$198.8M$215.8M$196.9M$170.2M$174.3M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$600K$550K$560K$530K$470K
Net debt-$-154.37M-$-154.85M-$-149.58M-$-98.26M-$-102.67M
Cash flow statement
20252024202320222021
Net income$23.3M$59.2M$68.1M$33.9M$69.5M
Depreciation and amortization$560K$540K$540K$520K$520K
Stock-based compensation$3.68M$3.64M$2.05M$1.78M$1.27M
Change in working capital$8.26M-$-4.69M$28.4M$9.44M-$-60.37M
Accounts receivable$17.9M-$-40K$24.3M$38.2M-$-80.31M
Inventory-$-850K$15.3M-$-25.52M-$-19.96M$140K
Accounts payable-$-580K-$-5.74M$2M$2.07M$1.47M
Net cash provided by operating activities$43.5M$48.8M$94.8M$41.6M$11.5M
Investments in property, plant and equipment-$-360K-$-40K-$-20K$0.00-$-50K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-360K-$-40K-$-20K$0.00-$-50K
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-430K-$-800K-$-11.07M-$-13.01M-$-26.02M
Dividends paid-$-43.12M-$-42.67M-$-32.14M-$-32.94M$0.00
Net cash used for financing activities-$-43.55M-$-43.46M-$-43.42M-$-45.96M-$-26.2M
Net change in cash-$-430K$5.25M$51.4M-$-4.35M-$-14.75M
Cash at end of period$155M$155.4M$150.2M$98.8M$103.1M
Operating cash flow$43.5M$48.8M$94.8M$41.6M$11.5M
Capital expenditure-$-360K-$-40K-$-20K$0.00-$-50K
Free cash flow$43.1M$48.7M$94.8M$41.6M$11.4M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About SIGA Technologies, Inc.

        SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.

        CEO
        Diem Nguyen
        Employees
        49
        Beta
        0.89

        Explore

        Frequently asked questions

        What is the intrinsic value of SIGA Technologies, Inc. (SIGA)?

        SIGA Technologies, Inc. (SIGA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SIGA undervalued?

        SIGA trades at a price of $2.40 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.